Insider buying last 90 days
No open-market insider purchases were filed for AMGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AMGN insider filing, plotted on the chart in Gekko.Open AMGN in Gekko
NASDAQ: AMGN
Amgen (AMGN) Stock Analysis & Forecast
$385.65+5.87 (+1.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryAmgen closes at $385.65, up 1.5%, sitting between its 50-day average of $400.27 and 200-day average of $360.35. The GekkoIndex reads 66.4, placing the stock in the Accumulation zone. Price stands 31.3% below Gekko Fair Value of $561.44. Over the past month the stock is down 12.8%, though it remains up 14.2% over three months and 40.4% over the past year.
This week's coverage centers on dividend comparisons, institutional positioning, and pipeline developments. One piece contrasts Amgen's dividend growth profile with Merck's, citing a higher current yield and more consistent raises. Nykredit A S disclosed a new stake of 135,233 shares valued at approximately $49 million, part of broader institutional ownership reported at 76.5% of shares outstanding. Separately, a fair value estimate from one analyst source moved to $388.03 from $371.93, with commentary noting both bullish views on the product portfolio and caution around patent and pipeline risks. On the product side, IMDELLTRA received an FDA update shortening post-infusion monitoring time, a change described as easing capacity constraints for oncology clinics. Also noted was a failed cholesterol-drug trial at Novartis, which the coverage frames as raising scrutiny on similar Lp(a)-targeting programs at Amgen and Eli Lilly.
Looking ahead, the next earnings date falls on 3 November 2026, 44 days out and after market close, with the last report showing EPS of $6.29 against an estimate of $5.60 and a 7.6% reaction. Analyst coverage spans 24 firms, with 9 buy, 13 hold, and 2 sell ratings, and a consensus target of $387.69. Seasonally, the next 20 trading days have averaged a 2.6% gain over five years, positive in 3 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $385.65200-day averageGekko Fair Value $561.44
Key stats
- Market cap
- $208.1B
- P/E ratio
- 23.4
- Forward P/E
- 15.4
- EPS, TTM
- $16.25
- Revenue, TTM
- $38.10B
- Profit margin
- 23%
- Dividend yield
- 2.60%
- Beta
- 0.43
- Volume
- 8.42M avg 2.82M
- 1-year return
- +40.4%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±4.8%
- 50-day average
- $400.27
- 200-day average
- $360.35
- Next earnings
- Nov 3 after close
- Shares outstanding
- 540.6M
Amgen swing-trade checklist
Amgen scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $385.65 sits between the 50-day ($400.27) and 200-day ($360.35) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.4, Accumulation
Reading 66.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
31.3% below
Price is 31.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 44 days
Next report Nov 3, 2026, 44 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Amgen stock chart and price history
Amgen closed at $385.65 on Sep 18, 2026, +40.4% over the past year, inside a 52-week range of $269.77 to $447.03.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.8%
- 3 months
- +14.2%
- 6 months
- +10.2%
- 1 year
- +40.4%
The full AMGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AMGN in Gekko
Follow Amgen through every session
Put AMGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AMGN in GekkoFree for 7 days. No credit card required.
About Amgen
Amgen develops medicines built on biological research, covering areas such as inflammation, cancer and blood disorders, bone conditions, heart and kidney disease, and brain-related illness. It is known for a wide roster of treatments, among them Enbrel for psoriasis and arthritis, Neulasta for infection risk during cancer treatment, Prolia for bone loss, Otezla for plaque psoriasis, and Repatha for reducing heart attack and stroke risk, alongside many other approved drugs.
Its medicines reach patients through healthcare providers such as doctors' offices, hospitals, dialysis centers and pharmacies, with products moving through pharmaceutical wholesalers as well as direct channels to patients. Amgen also works with other companies on research and drug development, including partnerships with firms such as Novartis, UCB, Bayer, BeiGene, Eli Lilly, Verastem and Kyowa Kirin, exploring new treatment combinations and antibody therapies for conditions like lung cancer and atopic dermatitis, alongside further research ties with Neumora Therapeutics.
Amgen was established in 1980 and is based in Thousand Oaks, California. Its shares are listed on the NASDAQ under the ticker AMGN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- amgen.com
Amgen GekkoIndex: the smart money zone
Amgen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.4, in the Accumulation zone, down 1.6 points over five sessions.
66.4Accumulation
Down 1.6 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | −1.0% | −5.2% | ||
| Accumulation (current zone) | 197 | +0.5% | +1.9% | ||
| Neutral | 386 | +0.2% | +1.9% | ||
| Distribution | 46 | +0.9% | −1.8% | ||
| Selling | 8 | Too few readings yet | |||
Average AMGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AMGN price, zone by zone.Track AMGN in Gekko
Is Amgen stock overvalued? Gekko Fair Value
Amgen trades 31.3% below Gekko Fair Value of $561.44, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Amgen shares are worth, recalculated every trading day.
$561.44
Gekko Fair Value, Sep 19, 2026
31.3% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AMGN in Gekko
Amgen insider and Congress trading
No open-market insider purchases were filed for Amgen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AMGN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AMGN, plotted on the chart in Gekko.Open AMGN in Gekko
Buybacks
Amgen has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2024
- $200.0M
- As a share of market cap
- 0.10%
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold AMGN.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Amgen earnings: next date and track record
Amgen reports on Nov 3, 2026, after the close (44 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 44 days away
- EPS estimate
- $5.78
- Revenue estimate
- $10.05B
7 of 8reports beat the EPS estimate
±5.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Amgen's Q2 2026 earnings call highlighted strong financial and operational performance driven by its six key growth drivers: Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, and Biosimilars. Total revenues exceeded $10 billion, up 10% year-over-year; 22 products delivered double-digit sales growth, and 17 products annualized over $1 billion. Management emphasized robust operating margins (48% non-GAAP), $3.5 billion free cash flow, and continued investment in R&D (+10% YoY) and capital expenditures (~$2.6B expected for 2026). The call reviewed pipeline progress: Repatha (VESALIUS-CV results, EU label expansion), Olpasiran (Lp(a) program with OCEAN(a) Phase III), MariTide (monthly/quarterly dosing potential; Phase III progress), dazodalibep (CD40L program in Sjögren's with Phase III underway), IMDELLTRA advancement and monitoring reductions, and other late-stage assets. Management reiterated BD strategy focused on small, early-stage assets in core therapeutic areas and capital allocation flexibility. CFO Peter Griffith announced retirement; Thomas Dittrich will be incoming CFO. Key metrics and themes: durable growth through loss of exclusivity, broad-based portfolio strength, prioritization of innovation investment, manufacturing scale-up, and shareholder returns (dividends and buybacks suggested).
- Guidance
- Company provided explicit operational guidance points: expected capital expenditures of approximately $2.6 billion in 2026. No specific revenue or EPS numeric guidance provided on the call beyond Q2 results and qualitative expectations for continued durable growth and increased patient reach in H2 2026.
- Risks flagged
- Mentioned challenges include competition from new entrants (e.g., oral PCSK9), pricing pressure (noted for Otezla and 340B exposure), operational complexity for therapies requiring monitoring (IMDELLTRA), clinical development risks (endpoint sensitivity for symptomatic Sjögren's; safety monitoring for dazodalibep), and dependence on successful late-stage trials (MariTide, Olpasiran, dazodalibep).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $6.29 est $5.60 | $10.05B est $9.43B | +7.6% |
| Apr 30, 2026 | $5.15 est $5.16 | $8.62B est $8.58B | −2.4% |
| Feb 3, 2026 | $5.29 est $4.72 | $9.87B est $9.47B | +6.2% |
| Nov 4, 2025 | $5.64 est $5.02 | $9.56B est $8.97B | +8.0% |
| Aug 5, 2025 | $6.02 est $5.28 | $9.17B est $8.94B | −5.7% |
| May 1, 2025 | $4.90 est $4.27 | $8.15B est $8.06B | −3.3% |
| Feb 4, 2025 | $5.31 est $5.08 | $9.09B est $8.88B | +6.6% |
| Oct 30, 2024 | $5.58 est $5.11 | $8.50B est $8.50B | +1.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Amgen stock forecast and analyst price targets
Analysts’ average 12-month price target for Amgen is $387.69, +0.5% from the last close, from 24 firms rating the stock in the last 90 days.
$387.69consensus 12-month target, +0.5% from the last close
Now $385.65Avg $387.69
Low $230High $460
Each firm’s latest rating in the last 90 days: 24 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Barclays | $380 | −1.5% |
| Sep 17 | Piper Sandler | $457 | +18.5% |
| Sep 17 | Truist Financial | — | — |
| Sep 17 | Scotiabank | $450 | +16.7% |
| Sep 17 | UBS | $430 | +11.5% |
+1.9%average 20-day move after past Accumulation readings
+2.6%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Amgen seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Amgen averaged +2.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.2% | 1 of 5 |
| Next 10 trading days | −0.5% | 1 of 5 |
| Next 15 trading days | −0.4% | 3 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +2.2% | 2 of 5 |
For scale, AMGN’s typical 20-trading-day move in either direction is about 4.8%.
Amgen market cap and key statistics
Amgen’s market cap is $208.1B, with a P/E ratio of 23.4 and revenue of $38.10B over the last twelve months.
Valuation
- Market cap
- $208.1B
- P/E ratio
- 23.4
- Forward P/E
- 15.4
- EPS, TTM
- $16.25
- Gekko Fair Value
- $561.44
Trading
- Volume
- 8.42M
- Avg volume, 20 days
- 2.82M
- 52-week high
- $447.03
- 52-week low
- $269.77
- Shares outstanding
- 540.6M
Financials
- Revenue, TTM
- $38.10B
- Profit margin
- 23%
- Return on equity
- 91.5%
- Quarterly earnings growth, YoY
- +64.9%
Risk and income
- Beta
- 0.43
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±4.8%
- Dividend yield
- 2.60%
Amgen stock news this week
Coverage of Amgen this week reads positive: 8 positive, 6 neutral and 4 negative headlines.
- Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?24/7 Wall St., Sep 19
- Nykredit A S Takes Position in Amgen Inc. $AMGNMarketBeat, Sep 19
- Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline RisksYahoo Finance, Sep 19
- Amgen (AMGN) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research, Sep 18
- How (AMGN) Movements Inform Risk Allocation ModelsStock Traders Daily, Sep 18
- Amgen stock heads into the open after a 1.34 percent dropAD HOC NEWS, Sep 18
Amgen peers
Amgen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| GILDGilead Sciences | Neutral | 3.4% above |
| MRNAModerna | Neutral | 44.3% above |
| NTRANatera | Distribution | 15.3% above |
| IQVIQVIA | Neutral | 10.6% above |
| UTHRUnited Therapeutics | Accumulation | 25.0% below |
| NBIXNeurocrine Biosciences | Buying | 38.9% below |
A peer links to its own page where one exists.
Amgen stock FAQ
What is Amgen’s market cap?
Amgen’s market cap is $208.1B at the Sep 18, 2026 close of $385.65, with 540.6M shares outstanding. The shares trade on a P/E ratio of 23.4.
What is the Amgen stock forecast?
The consensus analyst 12-month price target for Amgen is $387.69, +0.5% from the last close. Of the 24 firms that rated the stock in the last 90 days, 9 rate it a buy, 13 a hold and 2 a sell. Gekko doesn’t publish price predictions of its own.
Is Amgen stock overvalued or undervalued?
On Gekko’s estimate Amgen is undervalued: the Sep 18, 2026 close of $385.65 is 31.3% below Gekko Fair Value of $561.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Amgen report earnings next?
Amgen is expected to report on Nov 3, 2026, after the market closes (44 days away). Analysts expect earnings of $5.78 per share on revenue of $10.05B. Amgen beat the earnings estimate in 7 of its last 8 reports, moving 5.1% on average across the report.
What is Amgen’s 52-week high and low?
Amgen’s 52-week high is $447.03 and its 52-week low is $269.77; it closed at $385.65 on Sep 18, 2026, +40.4% over the past year.
Is Amgen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Amgen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.